In this episode, we delve into the controversial world of micro-dosing in sports. We'll explore how athletes are using psychedelics to enhance performance, the ethical implications of this practice, and the potential risks and benefits. Join us as we navigate this complex issue with our usual mix of scientific scrutiny and cultural analysis.

The final episode navigates the complex legal and regulatory landscape surrounding micro-dosing in professional settings. Host A investigates how different companies are developing policies around employee micro-dosing, from tech startups to traditional corporations, while Host B examines emerging legislative frameworks and clinical trial regulations. The hosts analyze specific cases where micro-dosing policies have been challenged in court, workplace drug testing implications, and the evolution of corporate wellness programs. The discussion culminates in exploring potential future scenarios for regulation and standardization of micro-dosing practices.

Our hosts investigate the relationship between micro-dosing and creativity through the lens of professional artists, musicians, and writers. Host A presents a series of creative output analyses from before and during artists' micro-dosing experiments, while Host B examines neuroscience research on psychedelics and creative cognition. The discussion covers specific dosing protocols used by different creative professionals, measures of creative output quality versus quantity, and the challenge of objectively assessing artistic enhancement. The episode concludes with an examination of historical examples of psychedelic use in art and their modern parallels.

This episode contrasts traditional antidepressant treatments with emerging micro-dosing approaches for depression management. Through detailed patient case studies, Host A explores how individuals are supplementing or replacing SSRIs with micro-dosing protocols, while Host B examines the latest clinical trial data on sub-perceptual psilocybin doses. The hosts debate the ethics of self-treatment, analyzing documented risks of drug interactions and the challenges of measuring long-term efficacy in uncontrolled settings. Special attention is given to the role of expectancy effects and the difficulties of conducting double-blind studies with psychedelics.

Our hosts examine how micro-dosing became embedded in Silicon Valley's work culture, starting with a deep analysis of a major tech company's unofficial policy toward employee psychedelic use. Host A presents interviews with anonymous developers and executives about their experiences with micro-dosing for productivity, while Host B analyzes the methodological flaws in self-reported performance improvements. The conversation explores the complex intersection of workplace enhancement culture, cognitive liberty, and corporate liability, culminating in a critical examination of whether tech industry practices are driving dangerous normalization.